Live Oak Private Wealth LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

Live Oak Private Wealth LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 236,061 shares of the biopharmaceutical company's stock after buying an additional 21,405 shares during the period. Live Oak Private Wealth LLC's holdings in Pfizer were worth $5,982,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Beam Wealth Advisors Inc. increased its stake in Pfizer by 1.5% during the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock worth $728,000 after buying an additional 401 shares during the period. Providence Capital Advisors LLC increased its stake in Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock worth $3,034,000 after buying an additional 409 shares during the period. Donaldson Capital Management LLC grew its holdings in Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock worth $947,000 after acquiring an additional 410 shares in the last quarter. Noesis Capital Mangement Corp grew its holdings in Pfizer by 2.6% during the 4th quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company's stock worth $434,000 after acquiring an additional 413 shares in the last quarter. Finally, First Command Advisory Services Inc. grew its holdings in Pfizer by 2.5% during the 4th quarter. First Command Advisory Services Inc. now owns 17,479 shares of the biopharmaceutical company's stock worth $464,000 after acquiring an additional 418 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.4%

Shares of NYSE:PFE opened at $23.97 on Monday. The stock has a market cap of $136.27 billion, a P/E ratio of 17.37, a P/E/G ratio of 0.87 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm has a fifty day moving average price of $23.26 and a 200 day moving average price of $24.89.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the business earned $0.82 EPS. The business's revenue was down 7.8% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.18%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.